NCT07346066招募中3 期
A Phase 3 Multi-Center Efficacy Study of Filricianine Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery Using the da Vinci Surgical System With Firefly® Fluorescence Imaging
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 146
- 试验地点
- 9
- 主要终点
- Independent reader assessment of ureter visualization by 1-5 Likert visualization rating scale from 1 not visible, 2 questionably visible, 3 low visibility, 4 visible, 5 clearly visible.
研究概览
简要总结
This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation
详细描述
Injury to the ureter, the duct by which urine passes from the kidney into the bladder, is a well-known and serious complication of pelvic and abdominal surgery that frequently goes unrecognized intraoperatively. This study seeks to evaluate the safety and efficacy of intravenous IS-001 injection to improve surgeon ureter visualization during robotic-assisted colorectal surgery with the da Vinci® Surgical System and Firefly® imaging.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female participants between the ages of 16 and 75, inclusive
- •Participant is scheduled to undergo robotic-assisted colectomy using the da Vinci X/Xi Surgical System with SFF Fluorescence Imaging
排除标准
- •1. Participant is pregnant or nursing
- •Participant has known current acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- •Participant has any of the following screening laboratory values: eGFR < 30 mL/min/1.73 m2
- •Aspartate aminotransferase (AST) ≥ 2.5 × ULN
- •Alanine aminotransferase (ALT) ≥ 2.5 × ULN
- •Total Bilirubin > 2mg/dL
- •Participant has any concomitant non-colorectal cancer
- •Participant has any circumstances that, in the judgment of the Investigator, might make them not a suitable candidate for the study
- •Participants have already been enrolled in another investigational drug or device study within the past 6 months
- •Participants with known or suspected hypersensitivity to indocyanine green (ICG) or any components of the formulation used
- •Participant is expected to receive or has received other methods for ureter identification during the surgery (e.g., ureteral stent placement, illuminated catheters, retrograde ICG injections) before the administration of IS-001
- •The duration of the surgery is expected to be less than 90 minutes as determined during preoperative planning.
研究组 & 干预措施
IS-001 Injection
Other
Ureter visualization and delineation will be compared between white light (standard of care) and near-infrared (NIR) imaging mode after each of the two single intravenous injections of IS-001.
干预措施: filricianine (Drug)
结局指标
主要结局
Independent reader assessment of ureter visualization by 1-5 Likert visualization rating scale from 1 not visible, 2 questionably visible, 3 low visibility, 4 visible, 5 clearly visible.
时间窗: 10 minutes after first injection
Evaluate ureter visualization by each independent reader at (a) the pelvic brim (PB) and (b) Inferior Mesenteric Artery (IMA) locations in Sensitive Firefly (SFF) mode compared to white light mode up to 30 minutes after the first IS-001 injection.
次要结局
- Independent reader assessment of ureter length delineation by line drawing on recorded frame measured in arbitrary unit length(30 minutes after the first injection)
- Independent reader assessment of ureter visualization by 1-5 Likert visualization rating scale from 1 not visible, 2 questionably visible, 3 low visibility, 4 visible, 5 clearly visible(30 miinutes after second injection)
- Independent reader assessment of ureter length delineation by line drawing on recorded frame measured in arbitrary unit length(30 minutes after second injection)
- Ureter visualization based on intraoperative surgeon's rating by 1-5 Likert visualization rating scale from 1 not visible, 2 questionably visible, 3 low visibility, 4 visible, 5 clearly visible(30 minutes after first IS-001 injection)
- Independent reader assessment of ureter visualization by 1-5 Likert visualization rating scale from 1 not visible, 2 questionably visible, 3 low visibility, 4 visible, 5 clearly visible.(45 minutes after first injection)
- Independent reader assessment of ureter visualization by 1-5 Likert visualization rating scale from 1 not visible, 2 questionably visible, 3 low visibility, 4 visible, 5 clearly visible(45 minutes after second injection)
- Concordance of ureter visualization between independent readers(10 minutes after first injection)
- Concordance of ureter visualization between independent readers(30 minutes after first injection)
- Concordance of ureter visualization between independent readers(45 minutes after first injection)
- Concordance of ureter visualization between independent readers(10 minutes after second injection)
- Concordance of ureter visualization between independent readers(30 minutes after second injection)
- Concordance of ureter visualization between independent readers(45 minutes after second injection)
- Concordance between intra-operative ureter visualization assessment and independent reader ureter visualization assessment(10 minutes after first injection)
- Concordance between intra-operative ureter visualization assessment and independent reader ureter visualization assessment(30 minutes after first injection)
- Concordance between intra-operative ureter visualization assessment and independent reader ureter visualization assessment(45 minutes after first injection)
- Concordance between intra-operative ureter visualization assessment and independent reader ureter visualization assessment(10 minutes after second injection)
- Concordance between intra-operative ureter visualization assessment and independent reader ureter visualization assessment(30 minutes after second injection)
- Concordance between intra-operative ureter visualization assessment and independent reader ureter visualization assessment(45 minutes after second injection)
- Degree of concordance of ureter visualization within independent readers(10 minutes after first injection)
- Degree of concordance of ureter visualization within independent readers(30 minutes after first injection)
- Degree of concordance of ureter visualization within independent readers(45 minutes after first injection)
- Degree of concordance of ureter visualization within independent readers(10 minutes after second injection)
- Degree of concordance of ureter visualization within independent readers(30 minutes after second injection)
- Degree of concordance of ureter visualization within independent readers(45 minutes after second injection)
- Ureter signal-to-background ratio evaluating contrast of fluorescent signal in NIR imaging mode(10 minutes after first injection)
- Ureter signal-to-background ratio evaluating contrast of fluorescent signal in NIR imaging mode(30 minutes after first injection)
- Ureter signal-to-background ratio evaluating contrast of fluorescent signal in NIR imaging mode(45 minutes after first injection)
- Ureter signal-to-background ratio evaluating contrast of fluorescent signal in NIR imaging mode(10 minutes after second injection)
- Ureter signal-to-background ratio evaluating contrast of fluorescent signal in NIR imaging mode(30 minutes after second injection)
- Ureter signal-to-background ratio evaluating contrast of fluorescent signal in NIR imaging mode(45 minutes after second injection)
研究者
研究点 (9)
Loading locations...
相似试验
招募中
2 期
A clinical trial investigating Iloprost as medication to improve bone healing in patients with upper arm bone fracture.2024-512468-71-00Charite Universitaetsmedizin Berlin KöR, Charite Universitaetsmedizin Berlin KöR30
已完成
不适用
Comparison of the Effectiveness of Intraoperative Intravenous Lidocaine and Intravenous Remifentanil in Postoperative Pain Management in Laparoscopic CholecystectomyNCT07312877Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization138
尚未招募
2 期
A phase 2 study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 Pembrolizumab, in stage III/IV unresectable melanoma patients with resistance to anti-PD1 checkpoint inhibitors (INTACT / MeRCI)2024-519326-20-00Philogen S.p.A.25
尚未招募
1 期
IASO206 in Patients With Relapsed/Refractory Multiple MyelomaNCT07322159Institute of Hematology & Blood Diseases Hospital, China12
尚未招募
2 期
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk FactorsNSCLCNCT07330076Tianjin Medical University Cancer Institute and Hospital28